Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paclitaxel + S-1 versus oxaliplatin + S-1 for first-line advanced diffuse-type gastric cancer
ChiCTR-TRC-13003139Phase 3Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Mar 2013
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of paclitaxel, tegafur and oxaliplatin in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoint: progression-free survival. Started Mar 2013; status: recruiting.
02
Drugs
paclitaxeltegafuroxaliplatin
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR-TRC-13003139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-13003139.